{"id":90999,"date":"2026-11-13T15:59:00","date_gmt":"2026-11-13T15:59:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=90999"},"modified":"2026-11-14T02:12:59","modified_gmt":"2026-11-14T02:12:59","slug":"oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/","title":{"rendered":"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff"},"content":{"rendered":"<p><em>Six 2026 Oncology Deals Worth Up to About USD 59 Billion Reshape a USD 279.73 Billion Market: Precedence Research Company Intelligence on Top Players, Investments, Approvals and Pipelines<\/em><\/p>\n<p>Ottawa, Nov.  13, 2026  (GLOBE NEWSWIRE) &#8212; <img decoding=\"async\" height=\"62.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/9daf58ab-2952-4db4-a4ab-ac696e530d14\/image1.png\" width=\"190.0px\" data-dpi=\"96\" data-filename=\"image1.png\" \/><\/p>\n<p><i>The global oncology market is valued at USD 279.73 billion in 2026, up from USD 250.88 billion in 2025, and is projected to reach USD 732.45 billion by 2035 at a CAGR of 11.31%. North America held 46% of 2025 revenue, and the U.S. market is set to grow from USD 81.26 billion in 2025 to USD 241.69 billion by 2035.<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"312.14px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/7c181209-66a9-4dff-bc5f-fc5addfbc15b\/image2.png\" width=\"554.93px\" data-dpi=\"72\" data-filename=\"image2.png\" \/><\/p>\n<p>Precedence Research today released updated company intelligence on the global <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DRZFBdR8KisDS2K5jWSmC1vCB2setKpFubQuBsBT1bFGSbwa3tG1a7ZYZBTW5o9737J0JO62CyN8IN0nwFO_tuyQbw4n2whs7OxiLj15jABcxCgFBMtKwhC-OlvCdG75\" rel=\"nofollow\" target=\"_blank\" title=\"oncology market\">oncology market<\/a>, covering cancer diagnostics and treatment, from <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M5W6_S0_8tuG3jeOtUx9GvlPRx7eTCOBz6fXk3nsNgvQkrCStxqkWYs071WBNF37BJEZ8PnVh7OVm1VM0z0UwDVNav0lA7_QhEK6PxwHYz5-vFpj5NxBfrecX6ni4Gcb\" rel=\"nofollow\" target=\"_blank\" title=\"chemotherapy\">chemotherapy<\/a> and immunotherapy to targeted drugs, cell therapies, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XTmJVXEpbGV2JL6cIkZbCO42Qoyz2FuBhUhyG0X2wpbG0xekPnmUeT7IycudaNhAVZF8krsWd--O8BlRhMwFiH1riSHKRLJc4otab3sFN3MJ5I8rynZrxddS29bgJ2Yb419nypWCNw38VWWqqQHCpBlgcXuJARCsZj8schycqg4=\" rel=\"nofollow\" target=\"_blank\" title=\"antibody drug conjugates\">antibody drug conjugates<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hSEa8u6GAVRj0FUqWFxPRUJ9FR4KF9d0im6vD9c6znSxERNV8AdgH6xlG05f1I-UQunZzJibdUa9b9zeZtiS2_A8UAAoOm4XYyXMsFGNxLG7z8_EvdFh8gYhqfE3XGaKuLwJFbdHR455kS7ghz7MPQ==\" rel=\"nofollow\" target=\"_blank\" title=\"radiopharmaceuticals\">radiopharmaceuticals<\/a>. The market is valued at USD 279.73 billion in 2026 and is forecast to reach USD 732.45 billion by 2035, adding USD 452.72 billion in annual revenue.<\/p>\n<p>This release focuses on the companies. Oncology is the largest therapy area in the pharmaceutical industry, and the leaders are posting strong sales: AstraZeneca&#8217;s oncology revenue reached USD 21.9 billion in the first nine months of 2026, up 16%, Merck&#8217;s Keytruda sold USD 8.6 billion in the third quarter, and Johnson &amp; Johnson&#8217;s Darzalex grew 15% to USD 4.24 billion. At the same time, the industry faces a patent cliff. Keytruda&#8217;s key U.S. patent begins to expire in 2028, and drugmakers are buying and licensing new assets to replace revenue.<\/p>\n<p>The result is one of the busiest years for oncology dealmaking. In 2026, GSK agreed to buy Nuvalent for USD 10.6 billion, Gilead agreed to buy Arcellx for about USD 7.8 billion, Merck acquired Terns for about USD 6.7 billion, Pfizer signed a collaboration with Innovent worth up to USD 10.5 billion, Curium agreed to acquire Lantheus for up to about USD 8.0 billion, and Roche partnered with Hansoh in a deal that could exceed USD 15 billion. The sections below cover who leads, how they are investing and where competition is heading.<\/p>\n<p><b>Full report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mkYDkLybq9UgAuTs2mqe5NTmfugTEY0ku6Zq0_D39cZM0Ahd7tdAkq0bWLOZeFX7PRby3Wdw3zcrbFTS1Mw-J0rm8JPILICxw9R3YR-AJWMQ-IB0B8fOuuQ2s4KO05bf0Nzjwh_d2fu3p5yF_RtRmoKFA8OadAPUxNLN5ZDODLw=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-market<\/a><\/p>\n<p><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mkYDkLybq9UgAuTs2mqe5NTmfugTEY0ku6Zq0_D39cbC3RFdbZqLxjYNJ3CgNkVQZOV_SA7QsrMJJKm-8ZUg-GFpFQ0-U4GQDoOPa4964nw9IOYz0P71a1lnOKEyZ_iwYWkYDKYEMk5BpyfZVT4_3Oa4OdA_4jwNa0K-6diEWWM=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/1467<\/a><\/p>\n<p><b>Market at a Glance: Size, Segments and Regions<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Market Indicator<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Value<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Market size, 2025 \u2192 2026<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 250.88 billion \u2192 USD 279.73 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Market size, 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 732.45 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CAGR, 2026\u20132035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">11.31%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Absolute growth, 2026\u20132035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 452.72 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. market, 2025 \u2192 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 81.26 billion \u2192 USD 241.69 billion (11.52% CAGR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest region, 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">North America (46%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading segment, 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Cancer treatment (about 56%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading \/ fastest indication<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Lung cancer \/ breast cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing end use<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Hospitals (10.9% CAGR)<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 1: Oncology Market Snapshot<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Oncology Market: Key Segments<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Segment<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>2025 Share<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>2026 Value (modeled)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Growth Signal<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Cancer treatment<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">~56%<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">About USD 156.65 billion<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Largest; immunotherapy, targeted drugs, ADCs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Cancer diagnostics and other<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">~44%<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">About USD 123.08 billion<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Most opportunistic; screening and molecular tests<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">North America (region)<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">46%<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">About USD 128.68 billion<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Largest region; U.S. drives launches<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>2026 values apply the published 2025 shares to the 2026 market size of USD 279.73 billion. Lung cancer is the largest indication and breast cancer the fastest-growing, which explains why lung and breast assets dominate 2026 deals and approvals. Europe is described as the most opportunistic region, and Asia Pacific is expected to grow significantly as China becomes a major source of new cancer drugs.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Top Companies and Latest Performance<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/39385b30-e557-4e8f-8d42-70f7d9b8634e\/image3.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image3.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 2: Top Oncology Companies, Latest Reported Performance<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The oncology market is led by large drugmakers with broad portfolios. Precedence Research names AstraZeneca, Roche, Johnson &amp; Johnson, Pfizer, Merck &amp; Co., Bristol Myers Squibb, AbbVie, Amgen, Takeda Oncology and BioNTech among the key players, alongside specialty companies and start-ups such as Grail, Faeth Therapeutics and ImmunoACT.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Key Oncology Brands<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Latest Reported Data<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Strategic Direction<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Merck &amp; Co.<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Keytruda, Keytruda Qlex, Welireg<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 Keytruda sales USD 8.6B (+6%); Qlex USD 830M<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Subcutaneous switch; Terns (CML); sac-TMT ADC; mRNA vaccine with Moderna<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AstraZeneca<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Tagrisso, Imfinzi, Enhertu, Datroway, Calquence<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">9M 2026 oncology revenue USD 21.9B (+16%), 47% of total<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ADC and early-line expansion; Enhertu and Datroway approvals (May 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Johnson &amp; Johnson<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Darzalex, Carvykti, Tecvayli, Rybrevant<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 Darzalex USD 4.24B (+15%); Tecvayli USD 312M (+77%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Myeloma leadership; bispecifics in earlier lines<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Bristol Myers Squibb<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Opdivo, Opdivo Qvantig, Breyanzi<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 growth portfolio +12%; 2026 revenue guide USD 49.75\u201350.25B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Subcutaneous Opdivo; cell therapy growth<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Roche<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Kadcyla, Polivy, Tecentriq<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hansoh collaboration could exceed USD 15B (Oct 2026)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">China-sourced pipeline; degrader conjugates with C4T<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pfizer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Padcev, Adcetris, Ibrance<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Innovent collaboration up to USD 10.5B (Jun 2026)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ADCs and multi-specifics after Seagen<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Novartis<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pluvicto, Lutathera, Kisqali<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 Pluvicto USD 674M (+20%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Radioligand therapy; mHSPC approval (Jul 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GSK<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Jemperli, Zejula, Blenrep<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Nuvalent acquisition USD 10.6B (Jun 2026)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Lung cancer targeted therapy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Gilead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Trodelvy, Yescarta<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Arcellx acquisition ~USD 7.8B (Feb 2026)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CAR-T in multiple myeloma<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AbbVie<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Venclexta, Elahere, Decnupaz<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Decnupaz approved May 27, 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ADCs in blood and ovarian cancers<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The leaders share three traits: a blockbuster immunotherapy or targeted franchise, a growing ADC or cell therapy business, and the cash flow to buy new assets. Merck and Bristol Myers Squibb are converting patients to under-the-skin versions of Keytruda and Opdivo to extend their franchises, while AstraZeneca is growing fastest among the leaders on the back of a broad portfolio.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Investments and Deals: How the Leaders Are Rebuilding Pipelines<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/479b70c9-0b88-4ea3-aad0-7859b56ef215\/image4.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image4.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 3: Largest Oncology Deals Announced in 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Date<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Acquirer \/ Partner<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Value<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Asset \/ Focus<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Feb 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Gilead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Arcellx<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 7.8B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Anito-cel CAR-T for multiple myeloma<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Mar\u2013Apr 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Merck<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Terns Pharmaceuticals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 6.7B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">TERN-701 oral therapy for CML<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Jun 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GSK<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Nuvalent<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 10.6B (cash, ~40% premium)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Zidesamtinib and neladalkib for lung cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Jun 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pfizer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Innovent<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Up to USD 10.5B (USD 650M upfront)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">ADCs with novel payloads, multi-specifics<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Aug 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Curium<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Lantheus<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Up to about USD 8.0B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Radiopharmaceutical diagnostics and therapy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oct 2026<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Roche<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hansoh<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Could exceed USD 15B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">China-sourced oncology pipeline<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>Together these six deals carry a potential value of up to about USD 59 billion. Three patterns stand out:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Patent-cliff replacement:<\/b> Keytruda generated roughly USD 31.7 billion in 2025, close to half of Merck&#8217;s revenue, and its U.S. compound patent begins expiring in December 2028. Merck&#8217;s Terns deal and its ADC and vaccine programs aim to fill that gap.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Lung cancer and blood cancers:<\/b> GSK&#8217;s Nuvalent purchase targets lung cancer, the largest indication, while Gilead&#8217;s Arcellx and Merck&#8217;s Terns deals target myeloma and leukemia.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>China as a source of innovation:<\/b> Pfizer\u2013Innovent and Roche\u2013Hansoh show that Western drugmakers are licensing Chinese assets at scale, mainly ADCs and multi-specific antibodies.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Key Company Developments<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/a7546f97-d86d-4d2f-972e-5dab91879247\/image5.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image5.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 4: Key Oncology Company Developments, 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Approvals are moving therapies into earlier disease.<\/b> In May 2026, the FDA approved AstraZeneca and Daiichi Sankyo&#8217;s Enhertu for two early-stage HER2-positive breast cancer settings and Datroway as first-line therapy for metastatic triple-negative breast cancer. On July 31, 2026, Novartis&#8217;s Pluvicto was approved for metastatic hormone-sensitive prostate cancer, nearly doubling its eligible population.<\/p>\n<p><b>What it indicates:<\/b> Earlier-line approvals expand treated populations and lengthen therapy, a key driver of the 11.31% market CAGR.<\/p>\n<p><b>New modalities are winning approvals.<\/b> AbbVie&#8217;s Decnupaz became the first ADC for blastic plasmacytoid dendritic cell neoplasm (May 2026). J&amp;J&#8217;s bispecific Tecvayli grew 77% in the third quarter of 2026.<\/p>\n<p><b>What it indicates:<\/b> ADCs, bispecifics, cell therapies and radioligands are taking share from older chemotherapy and single-target drugs.<\/p>\n<p><b>Subcutaneous versions are protecting franchises.<\/b> Keytruda Qlex generated USD 830 million in the third quarter of 2026, and Bristol Myers Squibb says Opdivo Qvantig is growing quickly.<\/p>\n<p><b>What it indicates:<\/b> Faster, under-the-skin dosing helps leaders keep patients ahead of biosimilar competition.<\/p>\n<p><b>Diagnostics are becoming more strategic.<\/b> Precedence Research identifies cancer diagnostics as the most opportunistic area, and Curium&#8217;s planned acquisition of Lantheus combines PSMA PET imaging with therapy.<\/p>\n<p><b>What it indicates:<\/b> Companies that pair tests with treatments (theranostics and companion diagnostics) will capture more of the patient journey.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Key Market Drivers<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Rising cancer incidence: new cases are projected to rise 47% between 2020 and 2040.<\/li>\n<li style=\"margin-bottom:4pt;\">Innovation in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rtU3MQ10o_SAzCj83saWMlYcdieNbVXAUwrNGF0GuriVZCGtzUzNe9Xve4nPcPRdpCAmnP78wOIDjQaW0gKH98H2n5pC--Pb5eqFJT6wFt8UGyIEy5-nM7E6VNNkurDxr5owVRGD_PiovND4M5LFYQ==\" rel=\"nofollow\" target=\"_blank\" title=\"precision medicine\">precision medicine<\/a>, ADCs, cell therapies and radioligands.<\/li>\n<li style=\"margin-bottom:4pt;\">Earlier screening and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1myNDA6pTceGIEPzU9nUdnnJaup3-MXDgulZW21phmeEPTvZG1Bwh3gIULeEwOgH_Lw9G8S1qiXx7UKsXODYed6_jehGjtlHR4-36JP2QwOUyr9tREEEMbGEgSBJ9nZNitkuaZJYKjvyPfmBnb_Kcg==\" rel=\"nofollow\" target=\"_blank\" title=\"cancer diagnostics\">cancer diagnostics<\/a> that find more treatable disease.<\/li>\n<li style=\"margin-bottom:4pt;\">Strong cash flows that fund acquisitions and licensing deals.<\/li>\n<li style=\"margin-bottom:4pt;\">Use of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0e_raGCDKFPg7hL_k9ODr5InJ5JM9pP2Dc7vnm_3HX2DRtNkPivz9w5hK5qWju6g3B7p0md4ghJpG6zK7feMWZQOV9zRUvjiU8ivbpdJY1z5qH4StBb1VcXVwbkSvmFQrGBKuum9SXdZ7P6fatmxIWmLbyRxeSYOD4wPHBtyN9gaXsJDN12rVkV_tt1fiV8Y\" rel=\"nofollow\" target=\"_blank\" title=\"artificial intelligence in oncology\">artificial intelligence in oncology<\/a> for drug discovery, imaging and trial design.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Major Challenges<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Patent expiries for top brands, led by Keytruda from 2028.<\/li>\n<li style=\"margin-bottom:4pt;\">High drug prices and growing price controls in the U.S. and Europe.<\/li>\n<li style=\"margin-bottom:4pt;\">Complex manufacturing for cell therapies, ADCs and radiopharmaceuticals.<\/li>\n<li style=\"margin-bottom:4pt;\">Rising competition from Chinese developers and biosimilars.<\/li>\n<li style=\"margin-bottom:4pt;\">High late-stage trial failure rates and costs.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Emerging Opportunities<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Breast cancer<\/b>, the fastest-growing indication, through ADCs and targeted therapy.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Cancer diagnostics<\/b>, the most opportunistic segment, including liquid biopsy and multi-cancer early detection.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Hospitals<\/b>, the fastest-growing end use at a 10.9% CAGR, as complex therapies concentrate in large centers.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>China licensing<\/b> for global rights to novel ADCs and multi-specifics.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Cancer vaccines and radioligands<\/b> as next-generation modalities.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company Ecosystem<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"446.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/b214a487-2b9e-4e2e-8ded-9653d02b4da1\/image6.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image6.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 5: Oncology Company Ecosystem, 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The supply side combines large drugmakers, biotech innovators (many now acquired or partnered) and diagnostics, imaging and service providers. The demand side includes hospitals and cancer centers, payers, specialty distribution and research bodies. Deals in 2026 moved several biotechs, including Nuvalent, Arcellx, Terns and Lantheus, into larger companies&#8217; portfolios.<\/p>\n<p><b>Customer and Buyer Intelligence<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target Account Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Decision-Makers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Purchase Signals<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Commercial Opportunity<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharma business development<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Head of BD, Oncology R&amp;D Head<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Patent expiries, pipeline gaps<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Licensing and M&amp;A targets<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Biotech companies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CEO, CSO, CFO<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Funding needs, late-stage data<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Partnering and exit strategy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hospitals and cancer centers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oncology Director, Pharmacy &amp; Therapeutics Committee<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">New approvals, capacity limits<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Infusion, cell therapy and radioligand programs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Payers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Medical Director, HTA Lead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Early-line approvals, budget impact<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Outcomes-based contracts<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Diagnostics companies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">BD Head, Commercial Lead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Companion diagnostic needs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Test\u2013drug partnerships<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>How Precedence Research Supports Decision-Making<\/b><\/p>\n<p><b>Master Dataset<\/b> provides segment, regional and company data for oncology and adjacent markets such as the cancer drugs<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DsQfvk0hRdDExBQyOSSzCpqCGBN6pfRuc23g77bzXs0nxtEjPWG5v4g4jQUeDwaN1CYMIUwOai3jjcuHU87JzbGqQyEpdRwGZQjPetldZyYC5o1xAsFJgFRQR8dUL8_eB9ROOGuBzOWn7-TziPr2eg==\" rel=\"nofollow\" target=\"_blank\" title=\", cancer therapeutics\">, cancer therapeutics<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5LFbuHfN8yLNfyDDGX2oBCzTRgs_f1SpsnYvywvuB4f7xNgX-ZZMnaTreMQMOGoL9ATAIRGhn3dUfvnUYs3JYiDd1xkTQtlspwea-ijNZ0-8VgUUwQYCxD5DXG1ZAcHmuX6IyFQnjhBTYoL4ydsXFg==\" rel=\"nofollow\" target=\"_blank\" title=\"precision oncology\">precision oncology<\/a> markets. It helps teams size demand by indication, modality and region.<\/p>\n<p><b>Precedence Quadrant<\/b> compares oncology companies on portfolio strength, pipeline, deal activity and patent exposure, helping business development teams screen partners and targets.<\/p>\n<p><b>Interactive Intelligence Dashboard<\/b> tracks approvals, deals, earnings and trial readouts, so strategy teams can respond to competitor moves quickly.<\/p>\n<p><b>Quality &amp; Manufacturing Intelligence<\/b> maps manufacturing capacity for biologics, ADCs, cell therapies and radiopharmaceuticals, supporting sourcing and partnering decisions.<\/p>\n<p><b>Customized Research<\/b> answers specific questions, such as patent-cliff exposure by company, China licensing valuations or the outlook for a given tumor type.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Solution<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>What It Provides<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>How It Helps<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Master Dataset<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Segment, region and company data on oncology<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sizes demand by indication and modality<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Precedence Quadrant<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Company comparison on portfolio, pipeline and deals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Screens partners and acquisition targets<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Interactive Dashboard<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Live tracking of approvals, deals and earnings<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Times BD, launch and investment decisions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Quality &amp; Manufacturing Intelligence<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Biologics, ADC, cell and radiopharma capacity<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Supports manufacturing partner choices<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Customized Research<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Patent-cliff, licensing and tumor-type studies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Answers decision-specific questions<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Why Continuously Updated Intelligence Matters<\/b><\/p>\n<p>Oncology changes faster than almost any other therapy area. Monthly updates suit business development teams tracking deals, approvals and trial data. Quarterly updates match company earnings, such as Keytruda, Darzalex and AstraZeneca oncology sales. Six-monthly updates align with major congresses such as ASCO and ESMO, and annual updates support investors reviewing market size, share and patent exposure. Precedence Research offers all four update cycles.<\/p>\n<p><b>Strategic Outlook<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>CEOs and CXOs:<\/b> the market adds USD 452.72 billion by 2035, but patent expiries mean growth must be bought or built now.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Strategy and business development teams:<\/b> 2026 deals worth up to about USD 59 billion set valuation benchmarks for lung cancer, CAR-T, ADC and radiopharma assets.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>R&amp;D leaders:<\/b> focus on breast and lung cancer, ADCs, bispecifics and radioligands, where approvals are moving into earlier lines.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Procurement and supply teams:<\/b> secure capacity for ADC conjugation, cell therapy and isotopes as new modalities scale.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Investors:<\/b> biotechs with late-stage lung, myeloma and ADC assets are prime acquisition targets.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Diagnostics and service providers:<\/b> pair tests with therapies to capture value in the most opportunistic segment.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Call to Action<\/b><\/p>\n<p>To understand which oncology companies, deals and modalities will lead through 2035, explore the full report or speak with a Precedence Research analyst.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVYisU1M8yRbFsLgvMoU7z2izHm4ad2H9XSqXedjaPKCrQsKzchZRPu7MVpA2IgR4KUp_z1FbHQmNhbz-JL-N1tAd8TplUlKulkcrsabABQFxAp-LnCq2omtx32paJ1DuQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-market<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLXVYTf5aw7fRiW0uSgrUmCvrJOQUIZkiFfhlICCBhNVpyR78SsXY-CFNb1bRZEtj78uMZ_o9dJXBd1mGJnjNyfTAGJXyIZhAEKC6N71yIPXsn25YRb2JtroTojpHbkAMJA=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/1467<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Schedule a meeting:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLW5nuKWiCP-xqUbxRkLyGHPzC5Z3kf9fS53OJJPpDroG2cB3fUqdjdYx9PkH_B44B5m0XvFPl7yqF_bcNU5ZZBJnn0w8bc6jqgWOcXgxZC6OL1AnenhwSxk6OuRE_TrNEM=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/schedule-meeting<\/a>\n<\/li>\n<\/ul>\n<p><b>Fill out the form for relevant samples, case studies, and examples.<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eA5_hHZyNDzF2fsJVozmf1oU0EBNOIPlD9wtm7ww3UACM46bfBr8g04hplpsPWTpGrJ5i9ctJHKh-kK6MbF93mSgRjkSBDfwDiV6uf3aEobdszdzUG1WEFV_lBANrzvl\" rel=\"nofollow\" target=\"_blank\" title=\"sales@precedenceresearch.com\">sales@precedenceresearch.com<\/a><\/p>\n<p><b>Related Reports<\/b><\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-bottom:3pt;\">Cancer Drugs Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVnIN0oeoZTqiN_Z5x_DLqcLARV6teufJ51N0nNlYC3a7sLvlF0XBIVjw8fZpxej-I5g5gTFbF6b-QxevPX_j2yQN1LWphusKyT9YCFD0vjo9LnUW8FEaC7oWLQc8_n4u6GNeo2HpXeTQiCoFEkcyCc\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Therapeutics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVnIN0oeoZTqiN_Z5x_DLqcUsVwLq-Uw6hjt4iidqI7g4yXMmVDukEtiWtGYRg-2Mln-p5Opct8k8LhOXJKppCyN2FM2lmE0E8HMIrRi-ma6YnvHRToxFkS1b47WU15-ElDvkSj3tqmSZZ_ZQ1pf-qoNPsPvP8qqIy57e38v8YJ6w==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-therapeutics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Precision Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVI_hp9sG2MTgQHB-q8PrnIUQ4YHHit9WBKtdG_otPL6nYQlZcsUrlnxt-YSA2awztQkyzSoDXjBZySLyfFoGJj2_qWEnJs6sA6wpPWvd8Pb3EA89JHxsxQzxe_ni2yltYM3kc4e6QD75-iWA9FR0h7\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/precision-oncology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Diagnostics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVnIN0oeoZTqiN_Z5x_DLqcOzFN3vFgXkzjA98Ia7KW0rLDRAzJQah0WIRYMzcIy9JP2wSGoE40mFvgpAhFpcTjDOHKLVikFH9vhiUSnhLQjwtFzfOajqVY8BKuwCLhE1_eYUYecKYct3deUNCtrH2o\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-diagnostics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Oncology Molecular Diagnostic Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVYisU1M8yRbFsLgvMoU7z22UTqj23srXYamuLMBNrgpv41GCi2KgBC9s45eJY1CEP-pBrhGjKb5TRepy08fGAq4R2LnFCGdV_-iIAoVw3VMo9k-bXj1OOSeD4I_dETdKwYTMuvE0ZOnwePd9NwqOCPjdoEdZRq7Qf0iSCU53UDhmJAC_7m8-PJCb9uJhzxPVo=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-molecular-diagnostic-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Artificial Intelligence in Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLUZ94Lby1ju6e205C3VTPRk46jTnptzMsns5mlvpKPaiAOpNSBdi1P3yazpgoGoOsdJQTRsK146IPLg8AZ_cLBhxUY-KYLt1z4rsEy5w4tUVzUUNACcznxsegMU9abZYiXVg94AitOGDPhJEoEqIXT5O79bR83DCe6V819FMek_1bDeG3anzX8TCuAzhxS9o__h9xjjNbRXZwKgN1iSue5n\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/artificial-intelligence-in-oncology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Non-Oncology Precision Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLXcwg36xJVIxUU92yVZ132Z6zXnHTZqbq8aFo0yB1B6fo7lrp6R9cKuMENJjwCSuEIZP0ye2IoMiu8BjGJS_frVoeWiZNiAZ8ssUidg7aX7vjR7wkNe5ngQWDvQ0w_j2jHhsS8ZxRbjmO0WXzvqL0cVCKHqoKcAGMKBTrVf21n71zYZPMhqXvolOLyGji3pPlo=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/non-oncology-precision-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Precision Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVI_hp9sG2MTgQHB-q8PrnI1H8R35IpmdoWZV8B4RX1PEaY8BsFpVAcyrwSjaFAavwq2yBkhVDLtFsceD-SQfaFdniiP7eFfVD9esjwtGjH2H3F3O0BsJo69E4m8_UUWnJkcBg5seZ6t0z-j3YsL6Zr\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/precision-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Chemotherapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLUlYfQ60aO_6-dq3EJ_L64-r_0YfTw_4GlSmpmy_xa69y_4p6yt4rQixO-Ha04UjRL2aP2_U2l28Nrvk3WUYmn29SKEi-D9XXy96_IZ4gb1hl9svBSS-DN7eXpKxZmesWXURZH4KKwotKHA02y-IBMP\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/chemotherapy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Antibody Drug Conjugates Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLWKLdymfB7ZoxtH0TYSvTuW3l4On3paVCdlapxUV7iVq5enMu9SKhVY86A8oqNTuFP4M6iEmPxYXEDd8LB9olU886G9USczXCRy7EQmP-x4Fam8j7J6o37P0VpkNBbxU2RWylftYQSwpAaRiv9bC8KJhuC8_RQsIDnqpRi9qBwE-A==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-drug-conjugates-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Radiopharmaceuticals Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVSqmJHr0BxBmaW3kN_GfEIR0rgAXel5-StJmBY_9j3PettQ_IU1GtmYFnITyrH0KfBDWwSakdt3jfR9cbvLUZBDbABnui2Y4dJQz7KN1crH0_ixGNcHhm8ZWmbxE-iF5wEp6rvb3x0j6HT14sQFC3ux5jgxTm4s4RiVuIgRaHsCA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/radiopharmaceuticals-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Nuclear Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLXA2Q6d4IiG5E9wUc74cqxx2KitpYQDIwKANIJTck-sCCj2jRGL0JlJYTapo7n-Bri5wGMMei3rdGL4mgRkyNYAhV_qFPr_VJkF0P4UwvMDcawwrdXP30AbT5wEAcwxkAulQk20UGsShyEMGFGTGAbu\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/nuclear-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Monoclonal Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLWgQ0xqkGwBKwTrFel-6GkIMP8ljuKhdjUruhasX_Mgw9k54h6mEBG4fT5esO6eIrcPujssjvyWLctMYkJrWWyfcDtJzAgJfuamd5aGe5lcHqua_f96ol5DMZ6HDrojI-zUSCFC69pTK48MihVD6LktK8YmBl_74hIhG26NwAWVCA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/monoclonal-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Monoclonal Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVnIN0oeoZTqiN_Z5x_DLqcZmLcRQIe9Qs2Q5MyTdwekua0cjgw2lV9jGbnFyJ1qfjLtIjHO0auZF01uv94Ff0jZT82Ci-wGDwRPiH0uAABNPpcQ0wKJD_16U_c4nADBD9J3Uq9tZCQSHAZOYi7Lcf8IvvDUY-tOmPGFcK6H1oAsHWN-ebJDe5FodwAmE916O4=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-monoclonal-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Bispecific Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLWxSQbD8u-pWqgfqkvKcSv-CwQdRwpmez9e-CMK7iIkhqzSTFG-OQ6vZ7wxg2Dt5VS05GPftpR44MmxqKhJiKMRf7x__eekjYr9yTzmElAnxK_tGzlFWiELh4wkxEKX3VFiIp-8ZPD-8B9i_KZVFtKeVBEtf6zJbfOoihbtFh2wqg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/bispecific-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Antibody Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLWKLdymfB7ZoxtH0TYSvTuW81KUcT_AQGUKn1LggdypeFh3eUkpjZnGSXfEW1i7SFKM7sOxwJFVpYhO7B3SDFH2KCWgyiNhTZriP4niqvT-iSiZYG3fQhlVVxb5tgKNaUpe_giihmSWYrx8FHwC3xsn\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-therapy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Clinical Trials Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLVZ5-PIOirhAGbF4uC2FLRY1axoqwpI7xlRXhlhZVrHgYthR_M8rqDaruFQjfn423C9w-IIGIXI6LJLVqSYv9bk7hGLIRb9PtzsWT2BnM5zSZGDMmjDJclSVWAvErqXsJK1i0TbAD4bxFC_9MmJ8yp1\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/clinical-trials-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biopharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLWxSQbD8u-pWqgfqkvKcSv-GSHDaprHYx7CfxsVW5p5dpeNoiKoQll_w1NWPnq3UVovOSLHgRg5uSYqo6fwLNOW656idnUukjN_cZOgItcyD9r_NZpEnQTzPCaQ_1lTN_--M6-xToSwD1VlkgK0je69\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biopharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLUbySZ51AmERoPhyO-YRrSkTtb29ETmbw9MgJm5vtvwWuLNEFEaYCxx3OQQzeEQd6mxjahKSjx2e5kM7yJv40c0xPnmaY2zt93pRJLMywIS-VOMHPTcV6qcKFs9usPq7zSk0oRka6zl7PAelCSKsNVm\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biotechnology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ03yKdepOwHVhc-QdnuXBLWxSQbD8u-pWqgfqkvKcSv-hBluoYuRrl98kltUugLowkO2W-sW-9fERO-8zV0u8NEDH8EbkTpQ4MVNePfSKNHsjCYYEMIO3QYdHNZztMw7EG41n0XvYhgMxFC3HZ3XTci147FtBtq5d62YfMEXf5fS\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biotechnology-market<\/a><\/li>\n<\/ol>\n<p><b>About Precedence Research<\/b><\/p>\n<p>Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, biotechnology, ICT, energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.<\/p>\n<p><b>Our Partners<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Towards Healthcare: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ-z2x853PiQwSkHxkguQ3my5rEpb5MTp6ms8MhXpiWFSHPNj-c68342E8eArRhfAH9W3dAeo1HVwzBbr5qI2V4o_2xWU1cCIGwvIyxwJALor\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardshealthcare.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Packaging: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ3v_7zYkndzBU1wPvuQp45UFFJAFz10NkECkDkR1BorBRKqtK6B_VtxZ7FTTYPahMMOemHZ81y3ACUW8Ge8WKAodIQUWje1x7J4tObNfwQU0\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardspackaging.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Chemical &amp; Materials: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ-Ta5WwdEa_vW8G1BwO7dPNH-DfrZwytDoqoiZkq5VxjwHPgVgRAVaOhtIQS_1MO9pwewycuAcG0Zr1F3JyB_hX2zEoRYQbNr7VxxN5bvDfudToBu0shW2zKZdUKSP8R6A==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardschemandmaterials.com\/<\/a>\n<\/li>\n<\/ul>\n<p><b>Connect With Us<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">USA: +1 804 441 9344<\/li>\n<li style=\"margin-bottom:4pt;\">APAC: +61 485 981 310 or +91 87933 22019<\/li>\n<li style=\"margin-bottom:4pt;\">Singapore: +65 3105 1271<\/li>\n<li style=\"margin-bottom:4pt;\">Europe: +44 7383 092 044<\/li>\n<li style=\"margin-bottom:4pt;\">Email: sales@precedenceresearch.com\n<\/li>\n<\/ul>\n<p><b>Social Media<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ3EFJu29xhwINQ1glXB0i4rGI40_xNXGqKqLICS8OxyfCZmwmLReA1rERLSTflivzhqaDag69JRA1VRunb3BkwGYC2GvAuJk8wIpF99_Gay6Pz0pYtW4lx1VY1bzphSn6dvoHUA4_I7m6HrP5Fr0G94=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.linkedin.com\/company\/precedence-research<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Facebook: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ7hj_JMnh959z4-PK43iQayEWBkYuIkzmHW8QjUE0pF28EQdxK3ngI-6bh-yaMKBg3pYIcn-dmXyB3po6VE8o_AqEpNqrR2P70mmtxR0gPm2pceju0FiZx7Jrk0wVVUDlw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.facebook.com\/precedenceresearch<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">X: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ7W58ArJGba6rDwJCGowwXxLw35_17abHEDc4-VrAIphzwMu7bIANQjWDDqU70uUFwFC9N4eP-fBGXBXOCzBoQ8=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/x.com\/precedence_r<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Medium: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No8kJnV--cYXkydNjSvWZ_7rwR45GgofFonD0inZ-UtJ0e3FD5c7hTvCXsXHomPtYmG1Ufp20YJ3Vd_S4HaNDNvUb0s8hEsi5sW2Oi4a9QyfWkY-I4fHlTN32FzSQ8vfced6lvmjUfeo6hkcIgOqPA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/precedence-research.medium.com\/<\/a><\/li>\n<\/ul>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MjE3YzljYTEtMjI3OS00N2UxLTkwMjItMTgzZmQ1Mzg2OTU2LTEyMTM4NDktMjAyNi0xMS0xMy1lbg==\/tiny\/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Six 2026 Oncology Deals Worth Up to About USD 59 Billion Reshape a USD 279.73 Billion Market: Precedence Research Company Intelligence on Top Players, Investments, Approvals and Pipelines Ottawa, Nov. 13, 2026 (GLOBE NEWSWIRE) &#8212; The global oncology market is valued at USD 279.73 billion in 2026, up from USD 250.88 billion in 2025, and [&#8230;]\n","protected":false},"author":1,"featured_media":91000,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-90999","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff\" \/>\n<meta property=\"og:description\" content=\"Six 2026 Oncology Deals Worth Up to About USD 59 Billion Reshape a USD 279.73 Billion Market: Precedence Research Company Intelligence on Top Players,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-13T15:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-14T02:12:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff.png\" \/>\n\t<meta property=\"og:image:width\" content=\"237\" \/>\n\t<meta property=\"og:image:height\" content=\"77\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff\",\"datePublished\":\"2026-11-13T15:59:00+00:00\",\"dateModified\":\"2026-11-14T02:12:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/\"},\"wordCount\":2491,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/\",\"name\":\"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-13T15:59:00+00:00\",\"dateModified\":\"2026-11-14T02:12:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/","og_locale":"en_US","og_type":"article","og_title":"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff","og_description":"Six 2026 Oncology Deals Worth Up to About USD 59 Billion Reshape a USD 279.73 Billion Market: Precedence Research Company Intelligence on Top Players,","og_url":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-13T15:59:00+00:00","article_modified_time":"2026-11-14T02:12:59+00:00","og_image":[{"width":237,"height":77,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff","datePublished":"2026-11-13T15:59:00+00:00","dateModified":"2026-11-14T02:12:59+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/"},"wordCount":2491,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/","url":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/","name":"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-13T15:59:00+00:00","dateModified":"2026-11-14T02:12:59+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/oncology-market-to-reach-usd-732-45-billion-by-2035-as-merck-astrazeneca-roche-jj-and-gsk-spend-billions-on-deals-to-beat-the-patent-cliff\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&amp;J and GSK Spend Billions on Deals to Beat the Patent Cliff"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=90999"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90999\/revisions"}],"predecessor-version":[{"id":91001,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90999\/revisions\/91001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/91000"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=90999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=90999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=90999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}